Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma

Table 3

Diagnostic performance of the urine test for the diagnosis of primary urothelial carcinoma.

Biomarker	Primary UC		%sensitivity (95% CI)	%specificity (95% CI)	%accuracy (95% CI)	%PPV (95% CI)	%NPV (95% CI)
	No. of patients
	Yes	No
NMP22			37.9	95.8	91.0	45.3	94.4
Positive	39	47	(28.5-48.0)	(94.5-96.9)	(89.4-92.6)	(34.6-56.5)	(92.9-95.7)
Negative	64	1078
^#
NMP22			41.7	83.3	61.1	74.1	55.6
Positive	20	7	(27.6-56.8)	(68.6-93.0)	(50.8-71.4)	(56.4-91.7)	(42.9-68.2)
Negative	28	35
Cytology			54.2	97.6	74.4	96.3	65.1
Positive	26	1	(39.2-68.6)	(87.4-99.9)	(65.3-83.6)	(80.6-99.9)	(52.0-76.7)
Negative	22	41
Combination			64.6	83.3	73.3	81.6	67.3
Positive	31	7	(49.5-77.8)	(68.6-93.0)	(64.0-82.6)	(65.4-92.4)	(52.7-79.8)
Negative	17	35

Note: patients performed the NMP22 BladderChek tests; ^#patients performed the NMP22 BladderChek tests and urine cytology tests; UC, urothelial carcinoma; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.